Back to search

Article

Efficacy and longevity of immune response to 3 <sup>rd</sup> COVID-19 vaccine and effectiveness of a 4 <sup>th</sup> dose in severely immunocompromised patients with cancer

2022-07-06

Abstract excerpt

Cancer patients show increased morbidity with COVID-19 and need effective immunization strategies. We demonstrate that a 3 rd dose of COVID-19 vaccine leads to seroconversion in 57% of patients that were seronegative after primary vaccination. The immune response is durable as assessed by anti-S antibody titers, T-cell activity and neutralization activity against wild-type SARS-CoV2 and BA1.1.529 at 6 months of f...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c4190ecd-f860-5892-810f-edb1759ba9d7
DOI
10.1101/2022.07.05.22277281
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficacy and longevity of immune response to 3 <sup>rd</sup> COVID-19 vaccine and effectiveness of a 4 <sup>th</sup> dose in severely immunocompromised patients with cancerDOI 10.1101/2022.07.05.22277281
Immune responses following third COVID-19 vaccination are reduced in patients with hematologic malignancies compared to patients with solid cancerSemantic proximity
Real-World Data on Neutralizing Antibody and Safety of COVID-19 Vaccine against SAR-CoV2 Wild Type and Omicron Variant in Solid Cancer PatientsSemantic proximity
Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelinesSemantic proximity
Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipientsSemantic proximity
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE studySemantic proximity
MicroRNAs immune response profile to COVID-19 vaccine boost in cancer patients under active treatmentSemantic proximity
Cancer Therapy and Immunogenicity of COVID Vaccine – CANINE StudySemantic proximity
Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron EraSemantic proximity
Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapySemantic proximity
Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccinationSemantic proximity
Immunogenicity and Omicron Neutralization Following a Third COVID-19 Vaccination in Solid Cancer Patients Previously Primed with Two Doses of Chadox1 Vaccine: A Prospective Cohort StudySemantic proximity
Humoral and Cellular Immunity to SARS-CoV-2 Vaccination in Cancer Patients: Completed Prospective Observational Study Using BNT162b2 mRNA VaccineSemantic proximity
Select a neighboring publication to make it the new centre.